Patrick Wood
Stock Analyst at Morgan Stanley
(3.17)
# 1,171
Out of 4,981 analysts
105
Total ratings
51.28%
Success rate
2.02%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Equal-Weight | $84 → $76 | $66.68 | +13.98% | 6 | Aug 28, 2025 | |
| ALC Alcon | Maintains: Equal-Weight | $84 → $80 | $78.29 | +2.18% | 5 | Aug 21, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $196 → $197 | $186.84 | +5.44% | 5 | Aug 11, 2025 | |
| STE STERIS | Maintains: Overweight | $276 → $295 | $249.88 | +18.06% | 7 | Aug 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $115 → $123 | $114.57 | +7.36% | 2 | Aug 1, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $12 → $13 | $15.19 | -14.42% | 8 | Aug 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $78 → $74 | $76.44 | -3.19% | 7 | Jul 31, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $71 → $68 | $37.14 | +83.09% | 3 | Jul 15, 2025 | |
| EW Edwards Lifesciences | Maintains: Equal-Weight | $75 → $81 | $77.57 | +4.42% | 9 | Jul 15, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $82 → $89 | $76.22 | +16.77% | 8 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $27 | $23.99 | +12.55% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $20 → $9 | $9.31 | -3.33% | 2 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $73.39 | +40.35% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $102.71 | +21.70% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $82.76 | -13.00% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $130.31 | +32.76% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $45 → $22 | $12.27 | +79.30% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $341.78 | -7.25% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $5.82 | +71.82% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $27.79 | +33.14% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $133.17 | - | 5 | Dec 11, 2017 |
The Cooper Companies
Aug 28, 2025
Maintains: Equal-Weight
Price Target: $84 → $76
Current: $66.68
Upside: +13.98%
Alcon
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $78.29
Upside: +2.18%
Becton, Dickinson and Company
Aug 11, 2025
Maintains: Overweight
Price Target: $196 → $197
Current: $186.84
Upside: +5.44%
STERIS
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $249.88
Upside: +18.06%
TransMedics Group
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $115 → $123
Current: $114.57
Upside: +7.36%
Bausch + Lomb
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $12 → $13
Current: $15.19
Upside: -14.42%
GE HealthCare Technologies
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $78 → $74
Current: $76.44
Upside: -3.19%
PROCEPT BioRobotics
Jul 15, 2025
Maintains: Overweight
Price Target: $71 → $68
Current: $37.14
Upside: +83.09%
Edwards Lifesciences
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $77.57
Upside: +4.42%
DexCom
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $82 → $89
Current: $76.22
Upside: +16.77%
Jul 15, 2025
Maintains: Underweight
Price Target: $28 → $27
Current: $23.99
Upside: +12.55%
Jul 15, 2025
Downgrades: Equal-Weight
Price Target: $20 → $9
Current: $9.31
Upside: -3.33%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $73.39
Upside: +40.35%
May 16, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $102.71
Upside: +21.70%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $82.76
Upside: -13.00%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $130.31
Upside: +32.76%
Mar 5, 2025
Downgrades: Equal-Weight
Price Target: $45 → $22
Current: $12.27
Upside: +79.30%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $341.78
Upside: -7.25%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $5.82
Upside: +71.82%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $27.79
Upside: +33.14%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $133.17
Upside: -